MEMORANDUM

SUBJECT: Talon (Brodifacoum) Anticoagulant Rodenticide. Tox Chem. No. 114AA

TO: William Miller, PM-16
Registration Division (TS-767)

THRU: Robert P. Jaeger, Section Head
Review Section #1
Toxicology Branch/HEP (TS-769)

FROM: Ray Landolt
Review Section #1
Toxicology Branch/HEP (TS-769)

Registrant: ICI Americas Inc.

Registration Nos. 1012-18, -40, -41, -48, -60,
-61, -26 and -26

Action Requested: Revise the "Note to Physician or Veterinarian" para-graph to include veterinary administration of Vitamin K₁, as follows:

This product may reduce the clotting ability of the blood and cause hemorrhaging. If poisoning occurs, intramuscular and oral administration of Vitamin K₁ are indicated, as in poisoning from overdose of bis-hydroxy coumarin. For human cases, Vitamin K₁ is antidotal at doses of 10-20 mg (not mg/kg). For animal cases, Vitamin K₁ is antidotal at 2-5 mg/kg. Repeated doses may need to be given up to two weeks (based on monitoring of prothrombin times). In severe cases, blood transfusions may be necessary.

Recommendation: The changes in the precautionary labeling for the treatment of the anticoagulant effects of brodifacoum with Vitamin K₁ therapy appear to be supported.
by the data submitted.

Toxicity Data Submitted with this Request:

I. A Comparative Study of the Effect of Warfarin and Brodifacoum on the Relationship Between Vitamin K1 Metabolism and Clotting Factor Activity in Warfarin-Susceptible and Warfarin-Resistant Rats.

Jasmin H. Lock and R. Kevin Park.


A. Procedure

The parameters investigated are prothrombin complex activity (PCA), clotting factor activity (CFA), vitamin K1 metabolism (bile and urinary metabolites). The test materials include both labeled and unlabeled vitamin K1, racemic sodium warfarin and brodifacoum.

Adult male Wistar Rats (200-300 g) and adult male Welsh warfarin-resistant rats (250-300 g) were used in these studies. Warfarin was administered I.P. to four animals per level of 0.1 and 1.0 mg/kg.

Brodifacoum was administered I.P. to four animals per level of 0.1, 1.0 and 10 mg/kg. Blood samples for measurement of PCA and CFA were collected from the tail artery. Blood for CFA was obtained at 24 hours and frozen for assay at the completion of the study, except for Factor V which was assayed within 2 hours of collection. For the metabolism studies, vitamin K1 was administered I.P., one hour after the administration of the anticoagulant followed by collection of blood by cardiac puncture, removal and homogenization of the liver two hours later.

To measure the rate of bile excretion vitamin K1 was administered one hour after the administration of the anticoagulant with bile collected at 10 minute intervals over a five-hour interval. For urinary metabolites, vitamin K1 was administered one hour after the administration of the anticoagulant with the animals placed in individual metabolism cages for urine to be collected every 12 hours over a 60-hour interval.

B. Results

1. Prothrombin complex activity (PCA) half life for brodifacoum was approximately 4 hours. Brodifacoum produced the same rate of PCA degradation in warfarin resistant rats as in warfarin-susceptible rats.
7. Clotting factor activity of vitamin K₁, except for Factor V, was significantly reduced by brodifacoum.

3. Brodifacoum increased the hepatic concentration ratio of labeled vitamin K₁ epoxide to labeled vitamin K₁ in both warfarin-resistant and warfarin-susceptible rats at anticoagulant dosages.

4. Brodifacoum, at anticoagulant doses, significantly increased labeled metabolites in the bile but did not alter bile flow.

5. Brodifacoum did not alter urinary excretion of labeled vitamin K₁ metabolites.

C. Conclusion

1. Classification of Data - Minimum

2. "The results indicate that brodifacoum has the same mechanism of action as warfarin and support the concept that coumarin anticoagulants reduce vitamin K₁ dependent clotting factor synthesis by interrupting the vitamin K₁ epoxide cycle."

II. A Study of the Effect of Anticoagulants on ³H Vitamin K₁ Metabolism and Prothrombin Complex Activity in the Rabbit. N. Kevin Park, et al.


A. Procedure

The parameters investigated are prothrombin complex activity (PCA) and vitamin K₁ metabolism. The test materials included both labeled and unlabeled vitamin K₁, racemic sodium warfarin, racemic acenocoumarol, Aifenacoum, brodifacoum and 2-chloro-3-naphthyl-1,4-naphthoquinone (Cl-K). Four adult male New Zealand White rabbits (2.5-3.0 kg) were used per dosage level. Warfarin, acenocoumarol and Cl-K were administered intravenously (I.V.) followed one hour later with labeled vitamin K₁ (I.V.) Difenacoum and brodifacoum were administered intramuscularly followed two hours later with labeled vitamin K₁ (I.V.). For PCA determinations blood samples were collected initially then at six hours after vitamin K₁ for four hour intervals. For vitamin K₁ metabolism blood was drawn at 1, 2, 3, 4, 5, and 6-hour intervals.
R. Results

1. Prothrombin complex activity half life for brodifacoum and difenacoum was approximately 7 hours. An approximate 6 hour PCA half life was reported for the other anticoagulants.

2. The approximate half life of labeled K1 for all five anticoagulants was approximately two hours.

3. The ratio of labeled vitamin K1 epoxide to vitamin K1 in the plasma increased with warfarin, acenocoumarol, brodifacoum and difenacoum, but decreased with Cl-K.

C. Conclusion

1. Classification of Data - Minimum

2. The pharmacological effect of warfarin by inhibiting vitamin K1 epoxide reductase appears similar for brodifacoum, acenocoumarol and difenacoum.

III. Investigation into the Effectiveness of Vitamin K1 as an Antidote to Brodifacoum Induced Anticoagulation in Rats.


A. Procedure

The parameters investigated are the effect of vitamin K1 therapy on mortality and prothrombin time due to warfarin and brodifacoum. Five Alderley Park pathogen-free (SPF) albino rats of each sex were used per dose level tested. Animals receiving oral doses were fasted 16-20 hours prior to dosing. Warfarin and brodifacoum were administered orally in polyethylene glycol. Vitamin K1 was administered intramuscularly at 2 mg/kg.

For the effect of vitamin K1 therapy on mortality, two groups of rats were dosed with brodifacoum at 0.25, 0.5, 0.75, 1.0 and 1.25 mg/kg. Control groups included warfarin (35 mg/kg), solvent (PPG 100) and an untreated group. One of the brodifacoum groups was treated with vitamin K1 and the other received no vitamin K1. The initial dose of vitamin K1 was administered 24 hours after brodifacoum, then repeated every 12 hours for eight days. A third group
received brodifacoum at 1.25 mg/kg and a single
dose of vitamin K₁ at 24 hours. All animals were
observed daily. Body weights were recorded initially
then on days 8, 15, 22, and 29. At the termination
of the study blood was drawn by cardiac puncture
for determination of prothrombin times and livers
removed and weighed.

For the effect of vitamin K₁ on these anticoagulants,
two groups of rats received brodifacoum at 1.25
mg/kg and warfarin at 35 mg/kg accompanied by
solvent and untreated control groups. One of the
test groups was left untreated the other was
treated with vitamin K₁ 24 hours later and repeated
every 12 hours for 9 days. All rats were observed
daily. At the termination of the study blood was
drawn by cardiac puncture for determination of
hemoglobin, hematocrit, WBC, RBC, mean cell volume,
mean cell hemoglobin concentration, differential
count and prothrombin time.

B. Results

1. Effect of Vitamin K₁ on Mortality from a Single
   Dose of Brodifacoum

   a. Untreated with Vitamin K₁

   The 1.25 mg/kg level killed 10/10 animals
   by day 6. At the 1.0 mg/kg level, 10/10
   animals died, males by day 6 and females by
   day 10. The 0.5 mg/kg dose killed 4/10 by
   day 6. No deaths 0/10 were reported for
   the 0.25 mg/kg level.

   b. Multiple dose of Vitamin K₁ (2 mg/kg every
      12 hrs. for 3 days). No deaths were reported
      for the 1.0 mg/kg level with 4/10 surviving
      the 1.25 mg/kg level.

   c. Single dose of Vitamin K₁ (2 mg/kg) to a
      1.25 mg/kg level of brodifacoum resulted in
      10/10 animals dead by day 7.

   d. Signs of toxicity reported for brodifacoum
   were depressed behavior, piloerection, uncooked
   and pale appearance, and subcutaneous hemorrhage.
   No decrease in body weight gain was apparent for the
   treated or untreated groups.
e. Liver weights relative to body weights of the treated and untreated groups were comparable to controls.

f. Clotting time of animals surviving the 28-day observation period were comparable to controls.

2. Effect of Repeated Doses of Vitamin K₁ on the Anticoagulant Brodifacoum and Warfarin.

a. Hematology after 2 days.

i. Male rats, treated and untreated with vitamin K₁, showed a significant increase in clotting time (5x control values), increased WBC, monocyte and lymphocyte count. Clotting time of warfarin rats treated with vitamin K₁ was comparable to controls.

ii. Female rats, treated and untreated with vitamin K₁ showed a significant increase in clotting time (5x control values) and monocyte count. Clotting time of warfarin rats treated with vitamin K₁ was increased 2–3 times as compared to control values.

b. Hematology after 4 days.

i. Male and female rats treated with vitamin K₁ showed a 4-fold increase in clotting times as compared to controls. Clotting times of female warfarin rats treated with vitamin K₁ were comparable to controls.

c. Hematology after 7 days.

i. Male rats, treated with vitamin K₁, showed a 2–3-fold increase in clotting time as compared to controls.

ii. Female rats, treated with vitamin K₁, showed a 3–4-fold increase in clotting time as compared to controls.

d. Hematology after 9 days treatment with vitamin K₁.

i. Male rats showed a 2-fold increase and females a 3-fold increase in clotting times.
C. Conclusion

1. Classification of Data - Minimum

2. Approximately acute oral LD₅₀ of brodifacoum is 0.5 mg/kg with repeated daily administration of vitamin K₁, the approximate LD₅₀ value increased to between 1.0 and 1.25 mg/kg.

Intramuscular doses of vitamin K₁ (2 mg/kg) repeated every 12 hours for 8 days is effective in reducing mortality from the anticoagulant effects of brodifacoum (1.0 mg/kg) in rats.

IV. An Evaluation of Vitamin K₁ Therapy in the Treatment of Brodifacoum Poisoning in Dogs.


A. Procedure

Fifteen dogs of mixed breed, age and sex were divided into three groups of five animals per group. Technical brodifacoum was administered in the feed at 3 mg/kg (L.D₅₀) to all three groups. Vitamin K₁ was administered as a single intramuscular dose of 2 mg/kg to two groups, one at 3 days and the other at four days after brodifacoum. The other group was untreated with vitamin K₁. All animals were fasted 24 hours prior to dosing. Prothrombin times were determined for all animals initially, two days prior to dosing with brodifacoum then at 2-3 day intervals.

B. Results

1. Dog oral LD₅₀ 3.56 mg/kg (Godfrey et al., 1981, M.Z.J. Exp. Anim. 9:147-149)

2. The controls, untreated with vitamin K₁, resulted in 3/5 deaths with lassitude, anorexia and bloody nasal discharge reported prior to death.

3. Treatment with a single dose of vitamin K₁ three days after brodifacoum when the prothrombin times were about twice of normal resulted in a near normal prothrombin time within 4 days of treatment followed by a regression and death (3/5).
4. Treatment with a single dose of vitamin K₁ four days after brodifacoum when the prothrombin times were about 3 to 4 times normal resulted in near normal values within 3 days of treatment followed by a three-fold increase in prothrombin at 10 days, then a return to normal in seven days with no deaths.

C. Conclusion

1. Classification of Data - Minimum

2. Vitamin K₁ (2 mg/kg IM) therapy in dogs should start no later than three days after ingestion of brodifacoum and repeated daily for at least four days or until prothrombin times return to normal.